Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYR-PB21 vs Bupivacaine in Healthy Participants
NCT07717086Phase 1Not yet recruiting
- Sponsor
- Fruithy Holdings
- Start
- Aug 2026
- Primary completion
- Sep 2026
01
Overview
Phase 1, randomised, single-blind trial of HYR-PB21 in postoperative pain (4 arms), sponsored by Fruithy Holdings. Primary endpoints: Maximum observed plasma concentration of bupivacaine at Day 14, Maximum observed plasma concentration of pamoic acid at Day 14 and 6 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
HYR-PB21
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT07717086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07717086.